Business
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Company to Host Conference Call, May 11, 2023, at 4:30 p.m. ET\nSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11. Title:Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Thursday, May 11, 2023Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-855-327-6837International: 1-631-891-4304Conference ID: 10021769Participants can use Guest dial-in #s above and be answered by an operator or click the Call me™ link for instant telephone access to the event.Webcast:Webcast Link - Click Here A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory ap...